Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShort-Term Debt repayments
Ratios

Cue Biopharma (CUE) Accumulated Depreciation & Amortization (2017 - 2025)

Cue Biopharma's Accumulated Depreciation & Amortization history spans 9 years, with the latest figure at $3.8 million for Q1 2025.

  • For Q1 2025, Accumulated Depreciation & Amortization changed N/A year-over-year to $3.8 million; the TTM value through Mar 2025 reached $3.8 million, changed N/A, while the annual FY2024 figure was $3.7 million, 1.77% up from the prior year.
  • Accumulated Depreciation & Amortization for Q1 2025 was $3.8 million at Cue Biopharma, up from $3.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $4.2 million in Q4 2022 and bottomed at $3.0 million in Q2 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $3.7 million (2024), against an average of $3.7 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization rose 28.98% in 2022 before it decreased 14.76% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $3.4 million in 2021, then rose by 23.18% to $4.2 million in 2022, then fell by 14.76% to $3.6 million in 2023, then increased by 1.77% to $3.7 million in 2024, then rose by 2.64% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Accumulated Depreciation & Amortization are $3.8 million (Q1 2025), $3.7 million (Q4 2024), and $3.6 million (Q4 2023).